Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies
- DOI
- 10.1007/s40264-024-01436-2
- Published
- 2024-06-01
- Container
- Drug Safety
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40264-024-01436-2,
title = {Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies},
author = {Adi Mor and Scott Friedman and Sharon Hashmueli and Amnon Peled and Massimo Pinzani and Matthew Frankel and Rifaat Safadi},
year = {2024},
journal = {Drug Safety},
doi = {10.1007/s40264-024-01436-2},
url = {https://doi.org/10.1007/s40264-024-01436-2}
}RIS
TY - JOUR TI - Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies AU - Adi Mor AU - Scott Friedman AU - Sharon Hashmueli AU - Amnon Peled AU - Massimo Pinzani AU - Matthew Frankel AU - Rifaat Safadi PY - 2024 JO - Drug Safety DO - 10.1007/s40264-024-01436-2 UR - https://doi.org/10.1007/s40264-024-01436-2 ER -
APA
Mor, A., Friedman, S., Hashmueli, S., Peled, A., Pinzani, M., Frankel, M., & Safadi, R. (2024). Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. Drug Safety. https://doi.org/10.1007/s40264-024-01436-2
Source records
- crossref · retrieved 2026-09-25T22:35:39.527Z